PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) — 23andMe Research Institute, a nonprofit medical research organization, today announced the formation of its Privacy Advisory Board. Composed of leading experts in health data privacy, data ethics, and consumer advocacy, the Board will provide strategic guidance on the protection of member information and the organization’s responsible stewardship of personal data.
“We have always been committed to giving individuals control over their data with choice and transparency,” said Anne Wojcicki, Founder and CEO of 23andMe Research Institute. “The establishment of this board, with its deep and diverse expertise, reflects our dedication to ensuring our policies and practices reflect the highest standards of data protection and ethical use while we continue to pioneer genetic discovery.”
The Privacy Advisory Board will advise 23andMe Research Institute on critical issues, including:
Members of the 23andMe Research Institute Privacy Advisory Board include:
The formation of the Privacy Advisory Board reinforces 23andMe Research Institute’s proactive approach to data privacy. It will help ensure the organization continues to innovate responsibly, while safeguarding sensitive personal information, and prioritizing the trust of our members and the research community.
About 23andMe Research Institute
23andMe Research Institute is a nonprofit medical research organization that enables people everywhere to access their genetic information, learn about themselves and participate in the world’s largest crowdsourced research initiative. The Institute aims to be the world’s most significant contributor to scientific advancement, uniting people with the common goal of improving health and deepening our understanding of DNA — the code of life.
Media Contact:
Catherine Afarian
23andMe Research Institute
408.656.8872
catherine.afarian@23andme.com
LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…
RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…
A summary of the current discussions in consumer health and wellness on the topic of…
LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…